Disclosure: I'm long ARIA as a substantial portion of my portfolio.
...which, in my opinion, means little. What was more important was the safety and efficacy demonstrated by AP26113 in the recently reported Phase II trial. If true, 113 should be able to make it swiftly through the approval process if the Phase II data continue to be positive, or perhaps after a limited phase III. People continue to be negative on 113 doing well in competition with the other major ALK inhibitors already approved (like crizotinib); the beauty of 113 is that it seems to have efficacy in various resistant mutants as well, which are a sizeable portion of non-small cell lung carcinomas. However, this is getting way ahead of where we are now; we still need to wait for more data to see if 113 is really effective, and safe. I'm still bullish on ARIA, and considering adding more to both the model portfolio and my real life portfolio.
Happy investing!
JVS
This is not a trade analysis or recommendation, but a comment on recent relevant news.
No comments:
Post a Comment